Roche Says In CT-996 Phase 1 Trial, 4-Week Weight Loss Was 5.8% In Second-Best-Performing Cohort Vs 1.2% Weight Loss In Placebo Cohort; Placebo-Adjusted Average Weight Loss Of 6.1% From CT-996 Obesity Pill Trial Was From 1 Of 3 Active Cohorts In The Phase I Trial; In CT-996 Phase 1 Trial, 4-Week Weight Loss Was 7.3% In Best-Performing Cohort With 6 Patients Vs 1.2% Weight Loss In Placebo Cohort
Author: Benzinga Newsdesk | September 11, 2024 11:49am